Thromboxane synthase inhibitors as insulin lowering agents and antiobesity agents
AssigneeHoffmann-La Roche Inc.
InventorsJames G. Hamilton, Ann C. Sullivan, Lawrence D. Tobias, Joseph Triscari
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of thromboxane synthase inhibitors as antiobesity agents and insulin lowering agents. Such compounds fall into a variety of classes among which are 1-substituted imidazoles, 4-substituted imidazoles, 3-substituted pyridines, 3-substituted indoles, 4-substituted pyrimidines, 5-substituted tetrazoles, pyrazolidines, quinazolines, and substituted xanthene carboxylic acids.
Claims11
A method for the lowering of insulin levels in mammals which comprise administering to the mammal to be treated a therapeutically effective amount of a thromboxane synthase inhibitor selected from the group consisting of 4-phenylpyrimidine, alpha-oxo-4-pyrimidinepropanoic acid ethyl ester and [6R-(6.alpha.,7.beta.)]-2-carboxy-8-oxo-3-[(4-pyrimidinylthio)methyl]5thia -1-azabicyclo-[4.2.0]oct-2-en-7-aminum hydroxide inner salt.
A composition for lowering insulin levels in mammals which comprises a pharmaceutically-acceptable carrier material and a therapeutically effective amount of a thromboxane synthase inhibitor selected from the group consisting of 4-phenylpyrimidine, alpha-oxo-4-pyrimidinepropanoic acid ethyl ester and [6R-(6.alpha.,7.beta.)]-2-carboxy-8-oxo-3-[(4-pyrimidinylthio)methyl]5-thi a-1-azabicyclo-[4.2.0]oct-2-en-7-aminum hydroxide inner salt.
Dependencies are inferred from the claim text.